NCT03983993 2026-01-05
NIPAVect
Emory University
Phase 2 Active not recruiting
Clinical Trials
35 trialsNCT02593175 2025-11-06
Women's MoonShot: Neoadjuvant Treatment With PaCT for Patients With Locally Advanced TNBC
M.D. Anderson Cancer Center
Phase 2 Completed
NCT01312857 2025-10-09
Study of Hepatic Arterial Infusion With Intravenous Irinotecan, 5FU and Leucovorin With or Without Panitumumab, in Patients With Wild Type RAS Who Have Resected Hepatic Metastases From Colorectal Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT03442569 2025-07-01
PhII Trial Panitumumab, Nivolumab, Ipilimumab in Kras/Nras/BRAF Wild-type MSS Refractory mCRC
UNC Lineberger Comprehensive Cancer Center
Phase 2 Completed
NCT03428958 2025-04-23
A Safety, Pharmacokinetic and Efficacy Study of NUC-3373 in Combination With Standard Agents Used in Colorectal Cancer Treatment
NuCana plc
Phase 1/2 Completed
NCT01814501 2025-02-05
Panitumumab and Chemotherapy in Patients With Advanced Colorectal Cancer After Prior Therapy With Bevacizumab
Ohio State University Comprehensive Cancer Center
Phase 2 Completed
NCT04117945 2024-09-27
Regorafenib, With Cetuximab or Panitumumab, for the Treatment of Unresectable, Locally Advanced, or Metastatic Colorectal Cancer
Academic and Community Cancer Research United
Phase 2 Active not recruiting
NCT03263429 2024-08-30
Novel PET/CT Imaging Biomarkers of CB-839 in Combination With Panitumumab and Irinotecan in Patients With Metastatic and Refractory RAS Wildtype Colorectal Cancer
Vanderbilt-Ingram Cancer Center
Phase 1/2 Completed
NCT01581840 2024-07-01
Radiochemotherapy With Panitumumab in the Localised Epidermoid Carcinoma of the Anus
Federation Francophone de Cancerologie Digestive
Phase 1/2 Completed
NCT03992456 2024-05-21
Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer
Academic and Community Cancer Research United
Phase 2 Active not recruiting
NCT01307956 2023-10-26
Panitumumab, Combination Chemotherapy, & Radiation Therapy in Esophageal or Gastroesophageal Junction Cancer
University of Nebraska
Phase 2 Terminated
NCT03733210 2023-05-19
Panitumumab-IRDye800 and 89Zr-Panitumumab in Identifying Metastatic Lymph Nodes in Patients With Squamous Cell Head and Neck Cancer
Stanford University
Phase 1 Completed
NCT01036087 2023-03-30
Panitumumab, Nab-paclitaxel and Carboplatin for HER2 Negative Inflammatory Breast Cancer
M.D. Anderson Cancer Center
Phase 2 Completed
NCT01504477 2020-03-16
Panitumumab and Bortezomib for Patients With Advanced Colorectal Cancer
Georgetown University
Phase 1/2 Terminated
NCT00948935 2020-03-11
Study of Gemcitabine, Irinotecan and Panitumumab in Patients With Advanced and Metastatic Biliary Tract Adenocarcinoma
Abramson Cancer Center at Penn Medicine
Phase 2 Completed
NCT01202409 2020-02-21
CAPOX in KRAS Wild-Type Advanced Adenocarcinoma of the Small Bowel or Ampulla of Vater
M.D. Anderson Cancer Center
Phase 2 Completed
NCT01057017 2020-02-17
First-Line FOLFOX-Bevacizumab for Advanced Colorectal Cancer With Wild-Type Ras
Brown University
Phase 2 Terminated
NCT01128387 2019-12-09
Trial of Panitumumab/Cisplatin/Fluorouracil Combined With Radiation in Esophageal Cancer
University of Wisconsin, Madison
Phase 1/2 Terminated
NCT00940316 2019-05-07
Dual Epidermal Growth Factor Receptor Inhibition With Erlotinib and Panitumumab With or Without Chemotherapy for Advanced Colorectal Cancer
Northwestern University
Phase 2 Completed
NCT02508077 2018-08-16
FOLFIRI and Panitumumab in Treating Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer
City of Hope Medical Center
Phase 2 Terminated
NCT01009983 2018-07-06
Paclitaxel, Carboplatin, and Panitumumab in Treating Patients With Metastatic Breast Cancer
Wake Forest University Health Sciences
Phase 2 Terminated
NCT00798655 2017-10-03
Trial of Postoperative Radiation, Cisplatin, and Panitumumab in Locally Advanced Head and Neck Cancer
University of Pittsburgh
Phase 2 Completed
NCT00842257 2017-05-16
Panitumumab in Cetuximab Refractory KRAS Wild-Type Colorectal Cancer
Massachusetts General Hospital
Phase 2 Completed
NCT00550836 2017-04-05
Erlotinib and Gemcitabine With or Without Panitumumab in Treating Patients With Metastatic Pancreatic Cancer
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT00601627 2017-04-05
Panitumumab, Chemotherapy, and External-Beam Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot be Removed by Surgery
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT00836277 2016-11-15
Phase II Study of Irinotecan and Panitumumab
University of Pittsburgh
Phase 2 Completed
NCT01042288 2016-05-11
Carboplatin, Pemetrexed, and Panitumumab in Patients With Advanced Non-Squamous K-ras Wild Type NSCLC
SCRI Development Innovations, LLC
Phase 2 Completed
NCT00757172 2016-03-11
Panitumumab, Docetaxel, Cisplatin, Radiation Therapy, and Surgery in Treating Patients With Newly Diagnosed, Locally Advanced Esophageal Cancer or Cancer of the Gastroesophageal Junction
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT01916109 2016-02-12
Study of Gemcitabine, Carboplatin, and Panitumumab (GCaP) as Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Terminated
NCT01296035 2015-08-25
PanGem
Women and Infants Hospital of Rhode Island
Phase 2 Terminated
NCT00578071 2015-07-02
POXX
Duke University
Phase 1/2 Completed
NCT01226719 2015-05-27
FOLFOXIRI Plus Panitumumab Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only
SCRI Development Innovations, LLC
Phase 2 Completed
NCT00894504 2015-05-15
Panitumumab, Gemcitabine and Carboplatin in Triple-Negative Metastatic Breast Cancer
SCRI Development Innovations, LLC
Phase 2 Completed
NCT01305772 2014-08-29
TOP0901
Duke University
Phase 2 Terminated
NCT01017653 2013-09-04
Panitumumab and Irinotecan for Malignant Gliomas
Duke University
Phase 2 Terminated